Open AccessA Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation
Author(s) -
Michael Cass,
Andrew McDonald,
Osnat BenShahar,
Yosef Landesman,
Trinayan Kashyap
Publication year - 2022
Publication title -
american journal of case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
ISSN - 1941-5923
DOI - 10.12659/ajcr.935353
Subject(s) - medicine , bortezomib , lenalidomide , multiple myeloma , dexamethasone , adverse effect , refractory (planetary science) , surgery , transplantation , autologous stem cell transplantation , salvage therapy , gastroenterology , oncology , chemotherapy , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom